-
1 month ago | 
nature.com | Philippe Moreau |Katja Weisel |Hartmut Goldschmidt |Saad Usmani |Robert Orlowski |Nizar Bahlis | +7 more
AbstractIn the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years).
-
Oct 11, 2024 | 
digitalcommons.library.tmc.edu | Payal Shah |Alexander Huang |Xiaowei Xu |Robert Orlowski
PURPOSE: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting the cell-surface antigen cMET. EXPERIMENTAL DESIGN: Metastatic melanoma or mTNBC subjects had at least 30% tumor expression of cMET, measurable disease and progression on prior therapy.
-
Sep 18, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MMThe relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.
-
Sep 11, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
OpinionVideoSeptember 11, 2024Author(s):The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies. Video content above is prompted by the following:What is your treatment sequencing approach for those who already received T-cell engaging therapies? What are some treatment options for those who have already received T-cell directed therapies in the R/R MM setting?
-
Sep 11, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.
-
Sep 4, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
OpinionVideoSeptember 4, 2024Author(s):The panel shares their expert impressions of the case and deliberates on potential treatment strategies for the 53-year-old patient with heavily pre-treated multiple myeloma, considering his prior therapies and current clinical status. Video content above is prompted by the following:Please describe your initial impressions of this case. How might you have treated or managed this patient in your clinical practice?
-
Sep 4, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
The panel presents and analyzes a case study of a 53-year-old man with heavily pre-treated multiple myeloma, including chemotherapy – based therapy and prior T-cell directed therapy, to illustrate treatment considerations and challenges in advanced disease management.
-
Aug 28, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
OpinionVideoAugust 28, 2024Author(s):The panel evaluates selinexor's current role in the treatment landscape for multiple myeloma and explores its potential future applications and evolving significance in therapeutic strategies. Video content above is prompted by the following:As the myeloma treatment landscape constantly evolves, where do you see selinexor fitting in? How might the future use of selinexor change? What are some key takeaways you can offer community colleagues?
-
Aug 28, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
The experts examine the available CAR T-cell therapy options for relapsed/refractory multiple myeloma.
-
Aug 21, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
OpinionVideoAugust 21, 2024Author(s):The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.
